The Pharma Data

JANUARY 6, 2021

Haydn Boehm is the Head of Commercial Marketing for Merck’s Connected Lab digital program and has over 20 years’ experience in marketing and business development within the life scientific sector. Dr. Pepe has a PhD in cancer biology and DNA repair and extensive experience in development and validation of cell-based assays.

Compound Screening 52

Compound Screening DNA Marketing Development 52

The Pharma Data

JUNE 7, 2023

In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA. “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Drug Discovery World

OCTOBER 18, 2023

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies. She received a Ph.D.

Gene Therapy 64

Gene Therapy Gene Clinical Trials Clinical Trials 64

pharmaphorum

APRIL 14, 2022

Managing CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala, CEO/Owner/Principal Consultant, Aurora CMC Consulting.

RNA 52

RNA Clinical Trials Clinical Trials Life Science 52

Drug Discovery World

APRIL 17, 2024

It had been known for decades that TFs, which orchestrate a cell’s gene expression programs, bind to DNA and proteins. He previously held key business development and operations leadership roles at leading biotech companies, including at Biogen and Genzyme.

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Drug Discovery World

JUNE 5, 2023

New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. The discussion answered three main questions: What is the new direction for the company?

Genome 52

Genome Genomics Life Science Genetics 52

The Pharma Data

JUNE 28, 2021

“Despite increased cancer survivorship overall, there continues to be significant unmet need in oncology,” said Marianne De Backer, MBA, PhD, Member of the Executive Committee of the Pharmaceuticals Division and Head Strategy and Business Development & Licensing at Bayer. “We

Licensing 52

Licensing Licensing Medicine Development 52

pharmaphorum

MARCH 8, 2022

After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. I have been general manager for Merck Healthcare UK & Ireland since 2020.

Life Science 98

Life Science Engineer Scientist Doctors 98

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0

Antibody 52

Antibody Sales Development Production 52

Drug Discovery World

APRIL 29, 2024

Hall has been with the company for more than 16 years, including as Chief Commercial Officer, and was previously Head of Business Development in Europe for Cyprotex. Bironneau brings over two decades of commercial leadership experience, including as Vice President, Global Sales & Business Development at Axplora and Novasep.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

MAY 16, 2023

Lentiviral vectors demand Naiara Tejados, Head of Marketing and Technology Development at VIVEbiotech & Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, anticipate that 2023 will be a very good year for VIVEbiotech, due to the increasing demand for lentiviral vectors.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

SEPTEMBER 6, 2022

Fully booked service providers for manufacturing and sample analyses and more immune-oriented use of gene and cell therapies.” – CBO Aino Kalervo, and VP of Business Development? .” – Andrew Scharenberg, Umoja Biopharma CEO. . Víctor Cervera-Carrascón, Tilt Bio. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

pharmaphorum

AUGUST 20, 2021

Simon Nicholson tells us how Organon, a new women’s healthcare company, is working to effect positive change globally by listening to women about their health care needs and allowing that information to drive their business development strategy. What’s Next?

Business Development 76

Business Development DNA Medicine Development 76

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7 kb Influenza A hemagglutinin gene was used as a model system.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

NOVEMBER 13, 2023

Yuchih Lin, Doctor, Sino Biological Europe, on: ‘Accelerating drug discovery using advanced antibody development platforms’. Ellen Hilgenberg, PhD, Senior Business Development Manager, Business Development, ProBioGen, on: ‘DirectedLuck for bispecifics – a transposase system streamlines cell line development’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

OCTOBER 26, 2020

The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. Business Developments. Merck and Seagen Inc. formerly known as Seattle Genetics, Inc.) Organon & Co.

Sales 40

Sales Vaccination Vaccine Production 40

XTalks

OCTOBER 1, 2020

Dr. Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. They felt there could be no one better than Dr. Lin to do business development and look for compounds that fit their drug delivery technology.

Scientist 52

Scientist In-Vitro Research Life Science 52

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. This stops the PARP from repairing any cancer cells, causing the cells to die.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

MAY 9, 2023

Jamaels recently brought together members of the business development team and new starters face-to-face for the first time to brainstorm how to remain competitive and price smarter. “When you have teams talking to each other and understanding each other’s requirements, then you can improve processes and raise the quality of the work.”

Clinical Trials 130

Clinical Trials Clinical Trials Trials Big Data 130